⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936049 | 0.94 | — | — | |
| SCHEMBL28654614 | 0.91 | ADH1B (0.31) | — | |
| SCHEMBL3939742 | 0.80 | — | — | |
| SCHEMBL3936046 | 0.75 | — | — | |
| SCHEMBL7296619 | 0.75 | — | — | |
| SCHEMBL12108502 | 0.73 | — | — | |
| SCHEMBL12108517 | 0.72 | — | — | |
| SCHEMBL12108508 | 0.71 | — | — | |
| SCHEMBL8913617 | 0.71 | — | — | |
| SCHEMBL24488829 | 0.66 | ADH1B (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107249642-A | Anti-Staphylococcus aureus antibody rifamycin conjugate and application thereof | 豪夫迈·罗氏有限公司 | 2017-10-13 | — | — | CN | disclosed |
| CN-107206102-A | Anti-Staphylococcus aureus antibody rifamycin conjugate and application thereof | 豪夫迈·罗氏有限公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-107206101-A | Quaternary ammonium compound and its antibody drug conjugate | 基因泰克公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-107106700-A | Peptide simulated compound and its antibody drug conjugate | 基因泰克公司 | 2017-08-29 | — | — | CN | disclosed |
| EP-2049536-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. | 2008-02-21 | — | — | US | disclosed |
| WO-2008011521-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | disclosed |